RYAN HOPSON: Open Payments
NPI 1316655079 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,220 in 116 payments from 13 companies in 2025. Trend: 2023 $2,068 · 2024 $2,568 · 2025 $2,220
Food & beverage: $2,220
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 13 | $341 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $338 |
| E.R. Squibb & Sons, L.L.C. | 13 | $244 |
| Otsuka America Pharmaceutical, Inc. | 15 | $235 |
| Lundbeck LLC | 6 | $216 |
| ABBVIE INC. | 15 | $190 |
| Neurocrine BioSciences, Inc. | 13 | $184 |
| Alkermes, Inc. | 6 | $163 |
| Janssen Pharmaceuticals, Inc | 6 | $153 |
| Axsome Therapeutics, Inc. | 4 | $67 |
Products named: CAPLYTA, REXULTI, HETLIOZ, COBENFY, VRAYLAR, INGREZZA, INVEGA SUSTENNA, ARISTADA.
Industry payments across KY — which companies pay providers there.
